Sequent Scientific - Manish Gupta, MD – 12-04-2018
- People confuse animal health to human pharma
- Ours is a similar indutsry to FMCG
- Animal health business is close to 900 crs on annual runrate basis
- 70% revenue comes from europe; India is less than 10%
- We are the only to have US FDA Approved Vet facility in the country
- Aspiration is to be in global top 10 in next 4 years - Revenues of 2000 crs (Current 800 odd crs)
- Expecting improvement in margins of 200bps yoy - will be closer to 20% in next 4 years time
- Growth will come from
- Organic growth - as it is branded generic industry; every year we claw some shares of other
- New product pipeline - 28 products under development
- Inorganic strategies - for some of the unrepresented market in our portfolio
- US and Australia are important veterinary geographies - Area of focus for inorganic growth
- API - As we grow in US - Growth will be price driven and not volume driven - will translate into margins
- We are focused on food producing animals (60% of global demand is in food producing animals)
- With demerger of human API business, we now are pure play animal health company
- Post demerger - effective debt is ~300 crs; have cash of 50 crs and investments in strides shares; net basis we are zero debt co.
Full Interview :